Between 1985 and 1998, 161 patients with primary acute myeloid leukemia (AML) received T-replete bone marrow transplantation (BMT) from unrelated donors in Seattle. Median age was 30 (range 1-55) years. Conditioning for BMT consisted of cyclophosphamide and total body irradiation in 154 (96%) cases and graftversus-host disease prophylaxis was the standard methotrexate and cyclosporine combination in 134 (83%) cases. Median post-transplant follow-up was 2.9 years. Leukemia-free survival (LFS) at 5 years was 50 ؎ 12% for transplants during first complete remission (n = 16), 28 ؎ 8% during second CR (n = 40), 27 ؎ 17% during subsequent CR (n = 8), 7 ؎ 3% during relapse (n = 81) and 19 ؎ 10% during primary induction failure (n = 16). The cumulative incidences of relapse were 19%, 23%, 25%, 44% and 63%, for the five groups, respectively. Transplantation during remission, a marrow cell dose above 3.5 ؋ 10 8 /kg, and cytomegalovirus seronegative status before BMT in both patient and donor were favorable prognostic factors. Adults in any CR who received a marrow cell dose above 3.5 ؋ 10 8 /mg had a LFS of 54 ؎ 9% at 5 years. These data extend our previous findings on the association between a high marrow cell dose and improved survival and support the use of unrelated donor BMT for treatment of patients with high risk AML when a family match is not available. Bone Marrow Transplantation (2000) 26, 397-404.
to 293 in 1998. [2] [3] [4] [5] [6] The number of HLA-typed volunteers in international donor registries now approaches six million and, as a result, it is possible to find HLA-compatible unrelated donors for 50-85% of patients who need an allogeneic transplant but lack a suitably matched relative. 7 Improvements in the precision of HLA-typing methods have allowed the selection of more closely matched donors, resulting in less severe graft-versus-host disease (GVHD) and better survival. 8, 9 Advances in prophylaxis and treatment of infection have also contributed to improved patient survival. As a consequence of these improvements, the results of unrelated donor BMT approached those of BMT from HLA-identical siblings. 10 The graft-versus-leukemia (GVL) effect provides an additional rationale for the use of BMT from unrelated donors 11 for the treatment of hematologic malignancies with high risk of relapse.
This report summarizes the Seattle experience for 161 patients who received unrelated donor BMT for AML. The study updates and extends the findings of a previous publication which included 74 patients. 12 In all cases, AML had features conferring a high risk of relapse which motivated unrelated donor BMT instead of autografts. The prognostic impact of marrow cell dose, a key finding of our previous study, has been confirmed among the new patients not included in the first report.
Patients and methods

Patients
Between 10 July 1985 and 15 July 1998, 161 patients with primary AML received unrelated donor BMT at the Fred Hutchinson Cancer Research Center. Patients with AML secondary to myelodysplasia, chemotherapy or radiation, and those transplanted with T cell-depleted marrow were excluded from this report. Table 1 shows the main characteristics of the study cohort. Twenty-six patients (16%) were less than 18 years of age, and 135 (84%) were adults. Seventy-five (47%) patients received unrelated BMT before 1994 and 86 (53%) thereafter (Table 2) . CT = chemotherapy; LAF = laminar air flow isolation rooms; mM = mismatch; N = nucleated cells; PIF = primary induction failure.
Disease characteristics
fied as good prognosis features including AML with inversion 16, translocation 8;21 or translocation 15;17 were seen in 18 patients (13%). Sixty-one patients (46%) had karyotypes indicative of poor prognosis. This included abnormalities of chromosomes 5 or 7, abnormalities of the long arm of chromosome 11, the translocation 6;9, and complex karyotypes. Fourteen patients with other abnormalities and 40 with a normal karyotype were assigned to the intermediate risk group (41%). All 16 patients transplanted in first CR had adverse prognostic features: unfavorable cytogenetics (n = 6), difficulty reaching CR (n = 6), megakaryocytic AML (n = 2), or persistent cytopenias with dysplastic marrow (n = 2). Seventy percent of the patients transplanted in second CR and 81% of those during first relapse had had a previous CR that persisted for less than 1 year. In 36 (45%) of the 81 patients in relapse no attempt had been made to induce another remission, whereas the remaining individuals (n = 45) were transplanted during chemotherapy-resistant relapse.
Histocompatibility studies and donor selection
The median time interval between initiation of the unrelated donor search and transplant was 4.2 (range, 1-19) months. HLA typing for all patients and donors was confirmed by the Fred Hutchinson Cancer Research Center Clinical Immunogenetics Laboratory. Histocompatibility studies for class I antigens consisted of serological typing according to a standard two-stage microtoxicity assay, 13 and antigens were assigned as defined by the World Health Organization HLA nomenclature committee effective at the time of transplantation.
14 HLA-DRB1 compatibility was assessed by hybridization of amplified DNA with sequence-specific oligonucleotide probes (SSOP) in 150 (93%) pairs. 15 In the remaining 11 (7%) pairs, HLA-DR typing was carried out with nylon wool-purified B cells in a modified microcytoxicity crossmatch assay 15 and 'Dw' assignments were made by stimulation with HLA-D homozygous typing cells in a standard HLA-D typing assay. 14 [6] ). When no HLA-identical donor was found, patients were eligible for one antigen-minor mismatch transplants if they were р36 year old. The distribution of HLA matching according to disease status appears in Table 2 .
Transplantation procedure
The Institutional Review Board of the Fred Hutchinson Cancer Research Center approved all treatment protocols. Written informed consent was obtained from adult patients and from parents or guardians of children Ͻ18 years old.
The main transplant characteristics appear in Table 2 . Seven patients (4%) were conditioned with chemotherapy alone while the remainder received cyclophosphamide (CY) plus total body irradiation (TBI) combinations. Hyperfractionated TBI was administered from dual opposing 60 Co sources with total exposure ranging between 13.20 Gy and 15.75 Gy.
Marrow cells were transported from the harvest center at ambient temperature, or at 4°C when transit times were expected to exceed 12 h and were administered intravenously after completion of the conditioning regimen. When major ABO incompatibilities were present, plasmaphereses or marrow red cell depletions were carried out before marrow infusion. In cases of minor ABO incompatibilities, plasma was removed from the marrow before the infusion. The numbers of nucleated marrow cells were not corrected for potential contamination with peripheral blood cells and ranged from 1 to 29.4 (median 3.5) ϫ 10 8 /kg recipient body weight. GVHD prophylaxis in 133 (83%) cases consisted of methotrexate and cyclosporine according to the schedule reported elsewhere. 16 
Engraftment
Myeloid engraftment was defined as the first of 3 consecutive days when the absolute neutrophil counts (ANC) exceeded 0.5 × 10 9 /l. Graft failure was defined as the lack of myeloid engraftment in patients surviving in remission for at least 28 days after transplantation. Platelet engraftment was defined as the first of 7 consecutive days when the platelet count exceeded 50 × 10 9 /l without transfusion support.
Acute and chronic GVHD
Criteria for diagnosis, grading and managing of acute and chronic GVHD have been reported elsewhere.
12,17
Statistical analysis
Results of the study were analyzed as of 15 April 1999. Prognostic factors influencing leukemia-free survival, nonrelapse death, and relapse were investigated. The variables Bone Marrow Transplantation included in the analysis were patient and donor ages, patient and donor gender, disease status, FAB subtypes, cytogenetic categories, pretransplant CMV serologies of donor and recipient, durations of donor search, HLA matching, intervals between CR and BMT, years of BMT, conditioning regimens, isolation measures, GVHD prophylaxis, and marrow cell doses. Kaplan-Meier curves were compared by the log-rank test. 18, 19 The Cox regression method was applied to perform the multivariable analyses. 20 Numeric variables were analyzed as categories considering their value above or below the median of the series as indicated in the results. The cumulative incidence rates of neutrophil and platelet engraftment, acute GVHD, chronic GVHD, non-relapse death, relapse, and the leukemia-free survival were calculated. 21 The definitions of leukemia-free survival, non-relapse death and relapse curves have been reported elsewhere.
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Results
Engraftment
Of 161 patients, 21 died within 28 days of transplantation, three with neutrophil counts above 0.5 × 10 9 /l. One hundred and forty patients were evaluable for hematological recovery since they were observed for at least 28 days, and all but two (1.4%) achieved sustained donor engraftment. The absolute neutrophil counts surpassed 0.5 × 10 9 /l at a median of 22 (range 7-34) days after transplantation. The cumulative incidence of a self-sustained platelet count above 50 × 10 9 /l was 50% and the median time was 25 (range 13-176) days.
Acute and chronic GVHD
The cumulative incidence rates of grades II-IV and III-IV acute GVHD were 77% and 41%, respectively, and the median time of GVHD onset was 16 (range 5-70) days. Sixty-seven patients surviving in remission for at least 100 days after transplantation were at risk for chronic GVHD. Fifty (65%) of the evaluable patients developed chronic GVHD with onset at a median of 104 (range 82-355) days after BMT. The cumulative incidence of any chronic GVHD was 66% and the cumulative incidence of clinical extensive chronic GVHD was 47%.
Non-relapse death
The 5-year cumulative mortality from causes other than recurrent leukemia was 43%. Eighty-one percent of these events occurred within the first 100 days and 19% thereafter. The cumulative incidence of non-relapse death according to the disease status at BMT is shown in Figure  1c . The results of the multivariable analysis showed that a marrow cell dose above the median (3.5 ϫ 10 8 cells/kg) was the only significant factor associated with a lower risk of non-relapse death (Table 3 ). The cumulative incidence of non-relapse death at 5 years in patients transplanted with a cell dose below the median was 53% vs 34% for those with a cell dose above the median (P = 0.006). The effect Bone Marrow Transplantation of marrow cell dose was especially evident in patients transplanted during remission (Figure 2b ). These patients had higher neutrophil counts (P = 0.002), fewer episodes of neutropenia with ANC below 0.5 × 10 9 /l during the initial 15 weeks after BMT (P = 0.007), and faster recovery of self-sustained platelet counts above 20 × 10 9 /l (P = 0.001). Patients transplanted with a cell dose below the median were more likely to die of bacterial infections and pneumonia, as we reported in a prior study (Table 4) .
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Table 4
Cause of death according to cell dose The cell dose is unknown for one patient. n = number; CMV, cytomegalovirus; RSV = respiratory syncytial virus.
Relapse
The cumulative incidence of relapse after transplantation was 39% with a median onset at 108 days (range 21 days-5.5 years). The incidence of leukemic relapse was significantly lower in patients transplanted during remission than in those transplanted during relapse or after primary induction failure (Table 3 , Figure 1b) . Patients in relapse with Ͻ30% leukemic blasts in the marrow and no circulating blasts before starting the conditioning regimen had a 37% incidence of relapse after BMT, those with у30% blasts in the marrow and no circulating blasts had an incidence of 44%, and in those with blasts in marrow and peripheral blood, the incidence was 50% (P = 0.02). There was no significant correlation between the incidence of relapse and the number of leukemic recurrences before transplant. Patients transplanted from HLA-mismatched donors had a similar incidence of recurrent leukemia as those transplanted from HLA-matched donors. In multivariable analysis, BMT during remission was associated with decreased relapse rates (Table 3) . Positive CMV serology of patient or donor was associated with increased relapse rates (Table  3) . This association was the result of relapse occurring earlier if either patient or donor was CMV seropositive rather than if both patient and donor were CMV seronegative. Relapse of malignancy occurred at a median of 105 (range 19-1455) days after transplantation if either patient or donor was CMV seropositive, and at a median of 216 days (range if both patient and donor were CMV seronegative. The incidence of relapse was similar in the two groups at 36 vs 37%.
Bone Marrow Transplantation
Leukemia-free survival (LFS)
Thirty-three (21%) of the 161 patients survive disease-free with a median follow-up of 2.9 (range 0.1-12.1) years. In multivariable analysis, the factors influencing LFS were disease status at BMT, marrow cell doses infused, and CMV serologies pretransplant (Table 3) . Transplantation from a one-antigen mismatched donor as opposed to an HLA-matched donor did not affect LFS. LFS at 5 years was 32 ± 9% in children below 18 years of age and 14 ± 4% in adults (P = 0.04). Patients transplanted during remission had better LFS than did those transplanted in relapse or after primary induction failure. Twenty-three (36%) of the 64 patients in CR at BMT, seven (9%) of the 81 in relapse and three (19%) of the 16 with primary induction failure remain alive without leukemia recurrence (Figure 1a) . The prognosis was best for recipients of BMT in first CR. Eight of the 16 patients transplanted during first CR survive leukemia-free after a median follow-up of 2 years. Among patients transplanted in relapse, the number of leukemia recurrences before BMT had no impact on outcome. Patients without circulating blasts at BMT (n = 33) had a 16 ± 6% 5-year LFS vs only 2 ± 2% in patients (n = 48) with blasts in marrow and blood (P = 0.02).
Patients receiving marrow cell doses above the median (3.5 ϫ 10 8 nucleated cells/kg) had significantly improved LFS (Table 3) . Among patients in relapse, those receiving marrow cell doses above the median had a 5-year LFS of 13 ± 6% vs 2 ± 2% for those receiving doses below the median (P = 0.2). Patients transplanted in CR with cell doses above the median had the best LFS (Figure 2a ). This finding was also observed in the patients transplanted after 1994 not included in our previous report (Figure 3a) . The positive effect of transplanting high marrow cell doses was not simply due to younger patient age. In adult patients, age 18 years or older, transplanted in CR the effect of cells dose was especially evident (Figure 3b ). LFS at 5 years was 47 Ϯ 12% for 20 patients of all ages in second CR transplanted with cell doses above the median (Figure 3c ). As shown in Table 3 , the CMV serologic status of donor and recipient before the transplant had prognostic impact with better outcome if both were sero-negative.
Discussion
The results of this study confirm that unrelated donor BMT is a treatment option for patients with high-risk AML who lack HLA-compatible family matches. 12, [23] [24] [25] [26] Disease status at transplant was the most important prognostic factor with best LFS for patients with less advanced leukemia. The outcome was most encouraging in patients grafted during first CR even though all had adverse features such as delayed achievement of remission, persistent myelodysplastic features, high risk cytogenetics or AML-M7 FAB subtype. 27 Several reports have shown that cytogenetic findings are the most important prognostic indicators in AML, with a dismal outcome for patients in the high risk group. 28 In this category, relapse rates approached 60% after autografts or BMT from HLA-identical siblings. [29] [30] [31] Cumulative incidence of relapse in the first CR patients of this study was 19% at 4 years, suggesting that BMT from unrelated donors is associated with a graft-versus-leukemia effect. Since the median duration of the donor search for patients in first CR treatment was 96 days, it is realistic to consider unrelated donor BMT as a feasible approach for high risk AML early in first CR provided the search process is initiated soon after diagnosis.
First CR duration was the most consistent prognostic factor associated with better LFS in patients receiving a BMT in second remission. Patients receiving autografts during second CR after a short first remission had a 4-year LFS of only 26 Ϯ 4%. 32 In our study, 70% of patients in second CR had a first CR of less than 12 months duration. LFS in this group was 38% at 5 years (data not shown), which might be better than expected with other therapies. Occasional patients with primary refractory AML may benefit from unrelated donor BMT. In this report, three of 16 patients are alive more than 5 years after the transplant. Patients transplanted in relapse had a very poor outcome with only 7% LFS at 5 years due to both high relapse rates and high mortality from non-relapse causes. More effective and yet more tolerable conditioning regimens will be needed for this group of patients. 33 We found that the outcome was comparable in patients receiving marrow from HLA-matched or one-antigen mismatched unrelated donors. Based on this finding, transplantation can be offered to a broader proportion of patients with acute leukemia who do not have HLA-matched donors. Negative pretransplant CMV serologies in donor and recipient were associated with better LFS. Of note in this study was the finding that negative CMV serologies in donors and recipients were associated with delayed rates of relapse. The association of CMV serology with delayed relapse was independent of patients age and disease stage. Reasons for this association are unclear. In most previous studies, negative CMV serologies were associated with a lower incidence of non-relapse death. 34 The primary finding of our previous report was that higher marrow cell dose is a key factor associated with lower non-relapse death and improved LFS. 12 Transplantation of high doses of marrow cells was associated with more robust neutrophil engraftment, accelerated platelet recovery and decreased mortality from transplant complications. The marrow cell dose effect was confirmed in the cohort of patients transplanted since 1995, who were not included in our previous report. The positive effect of transplanting a high number of nucleated or CD34-positive marrow cells has also been reported for patients who have received autografts or allografts from HLA-identical siblings. [35] [36] [37] [38] [39] In the present study, the association of a higher marrow cell dose with improved LFS was most prominent in patients transplanted during CR.
The number of cells that can be harvested from the marrow is limited, large numbers of stem cells can be collected by peripheral blood apheresis after treatment of the donor with hemopoietic growth factors. 40 There is now extensive experience with transplantation of growth factor-mobilized peripheral blood stem cells from HLA-identical siblings, and it is known that this procedure is associated with more rapid hematological recovery 41 and possibly improved immune reconstitution compared to BMT. 42 Data from the European Blood and Marrow Transplant Group indicate that the number of peripheral blood stem cell transplants from unrelated donors has increased from 11 in 1994 to 240 in 1998. [1] [2] [3] [4] [5] [6] A recent study has shown the use of peripheral blood stem cells for hematopoietic transplantation from unrelated donors to be associated with faster hematological recovery and no increase in acute GVHD when compared to BMT. 43 There is the concern for a possible increase in chronic GVHD if peripheral blood stem cells are used for transplantation, 44, 45 but data from HLA-identical siblings indicate that the increased incidence of chronic GVHD associated with the use of peripheral blood stem cells may not result in decreased survival. 44, 45 All available preliminary data and our findings reported here support further investigation into the use of mobilized peripheral blood instead of bone marrow from unrelated donors as a source of a high number of stem cells for transplantation in patients with AML. The hypothesis to be tested is that the use of peripheral blood stem cells for patients with AML may lead to decreased transplant-related mortality and improved LFS.
